Shuang G. Zhao
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (30)
Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus, we sought to identify the intrinsic molecular subtypes of mCRPC and assess molecular and clinical correlates in the largest combined cohort of mCRPC samples with gene expression data available to date. Experimental Design: We combined and batch-effect corrected gene expression data from four mCRPC cohorts from the Fred Hutchinson Cancer Research Center ( N = 157), a small-cell neuroendocrine (NE) prostate cancer (SCNC)–enriched cohort from Weill Cornell Medicine ( N = 49), and cohorts from the Stand Up 2 Cancer/Prostate Cancer Foundation East Coast Dream Team ( N = 266) and the West Coast Dream Team ( N = 162). Results: Hierarchical clustering of RNA-sequencing data from these 634 mCRPC samples identified two distinct adenocarcinoma subtypes, one of which (adeno-immune) was characterized by higher gene expression of immune pathways, higher CIBERSORTx immune scores, diminished ASI benefit, and non–lymph node metastasis tropism compared with an adeno-classic subtype. We also identified two distinct subtypes with enrichment for an NE phenotype, including an NE-liver subgroup characterized by liver metastasis tropism, PTEN loss, and APC and SPOP mutations compared with an NE-classic subgroup. Conclusions: Our results emphasize the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, and suggest that future studies should consider incorporating transcriptome-wide profiling to better understand how these differences impact treatment responses and outcomes.
Year:
2025
Supplemental Table 1: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 2. Supplemental Table 2: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 3. Supplemental Table 3: Proportions for Figure 4. Supplemental Table 4: Proportions for Figure 5.
Year:
2025
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternate metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment-resistance. We identify the poorly studied metabolic enzyme Oxoglutarate Dehydrogenase-Like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme Oxoglutarate Dehydrogenase (OGDH), as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA Damage in prostate cancer. While OGDHL has been described as a tumor-suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL profoundly alters Androgen Receptor inhibition-induced plasticity, including suppressing the neuroendocrine markers DLL3 and HES6, induces accumulation of the DNA damage response marker ƔH2AX, and reduces nucleotide synthesis. Our data suggest that OGDHL has minimal impact on TCA cycle activity, and that mitochondrial localization is not required for its regulation of prostate cancer plasticity and nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine differentiation in clinical prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer.
Year:
2025
Cell-surface target expression is variable across CTC phenotypes. A, Heatmap of gene expression of cell-surface targets ordered by clustering in Fig. 1D . B–J, Cell-surface target expression by CTC phenotype for targets associated with prostate adenocarcinoma ( KLK2 , STEAP1 , and STEAP2 ), pan-cancer cell-surface targets expressed in prostate cancer including TACSTD2 (TROP2), ERBB2 (HER2), and tumor immune checkpoint cell-surface protein CD276 (B7H3), as well as targets associated with prostate neuroendocrine differentiation ( DLL3 , CEACAM5 , and SSTR2 ). For patients with multiple CTC samples, the highest purity sample is included (Low_CTC, n = 30; Low_prolif, n = 12; LumA, n = 24; LumB, n = 31; and NE, n = 3). Low_CTC samples are included for reference but not included in statistical comparisons because they are expected to have low/no expression due to low CTC content.
Year:
2025
RNA-seq of high-purity CTCs isolated from patients with metastatic prostate cancer reveals four transcriptional phenotypes. A, Tumor/CTC purity was assessed using the ESTIMATE algorithm in prostate cancer cell line samples ( n = 12, green), CTC samples processed with standard-stringency ( n = 41, blue) or novel high-stringency ( n = 211, orange) method; healthy donor blood samples processed analogous to novel high-stringency CTC samples ( n = 12, pink) and a published dataset of mCRPC tissue biopsies separated by biopsy site ( n = 629, gray). ESTIMATE score is plotted for each sample. B, ESTIMATE tumor fraction (left) and CIBERSORTx immune content (right) scores for standard-stringency ( n = 41, blue) or high-stringency ( n = 211, orange) CTC methods are plotted and compared with prostate cancer cell lines ( n = 12, green). C, Assessment of the number of samples meeting high-purity threshold for standard-stringency vs. high-stringency methods. D, Consensus k -means clustering of single-sample pathway z -scores of 146 high-purity CTC samples from 70 patients with metastatic prostate cancer identifies four distinct clusters. CRPC, castration-resistant prostate cancer.
Year:
2025
Luminal-B CTC phenotype and persistent PSMA expression are associated with poor response to 177 Lu–PSMA-617. A, Clinical benefit rate (the best radiographic response of stable disease, partial response, or complete response) for 177 Lu–PSMA-617 in patients with favorable pretreatment CTC phenotypes (Low_CTC, LP, and LumA) vs. pretreatment LumB phenotype. B, Proportion of pretreatment LumB vs. favorable CTC phenotypes for patients with and without 177 Lu–PSMA-617 early progression (disease progression within the first three cycles/18 weeks of treatment). C, Baseline CTC FOLH1 (PSMA) gene expression for LumB ( n = 8) vs. favorable CTC phenotypes ( n = 29). Kaplan–Meier plot for ( D ) radiographic progression-free survival (rPFS) and ( E ) OS illustrates decreased rPFS and OS after starting 177 Lu–PSMA-617 for patients with the pretreatment LumB CTC phenotype. F, Longitudinal evaluation of consensus AR/luminal and neuroendocrine pathway scores during 177 Lu–PSMA-617 treatment. Patient 818 (left) represents an example of a patient with early progression on 177 Lu–PSMA-617 who demonstrated a rapid increase in NE score and decrease in AR score on treatment. Patient 978 (right) illustrates a patient with a longer duration of response who also shows an increased NE score and decreased AR score at the time of disease progression.
Year:
2025
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by androgen receptor alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance has been limited by the challenges of collecting serial tissue biopsies on treatment, which can be overcome using blood-based liquid biopsies. Using a novel circulating tumor cell (CTC) isolation approach, we collected 273 CTC samples from 117 patients with metastatic prostate cancer for RNA sequencing. One hundred forty-six samples from 70 patients had tumor purity comparable with tissue biopsies. We identified four CTC transcriptional phenotypes, mirroring lineage states identified in the tissue. Patients with a luminal-B–like CTC phenotype defined by persistent androgen receptor signaling and high proliferation, as well as those with a neuroendocrine CTC phenotype, had significantly shorter survival than patients with luminal-A–like and low proliferation phenotypes. In a prospective substudy, pretreatment CTC luminal-B–like phenotype was associated with early progression on 177 Lu–PSMA-617. Significance: Treatment resistance remains a universal driver of lethal metastatic prostate cancer, associated with acquired genomic alterations and lineage transitions. Using a novel high-purity CTC isolation approach for CTC transcriptional profiling, we identified four lineage phenotypes differentially associated with prognosis in metastatic prostate cancer.
Year:
2025
Classification of mCRPC tissue biopsy samples and low-purity CTC samples into the high-purity CTC phenotypes recapitulates survival differences. A, Classification of mCRPC tissue biopsy samples ( n = 203) with a k -nearest neighbor (KNN) classifier trained on the high-purity CTC sample phenotypes recapitulates the differences in survival outcome seen between the four CTC phenotypes. B, Low CTC burden (Low_CTC) samples with at least minimal epithelial gene expression defined as an expression sum of four epithelial markers (EpCAM, KRT8, KRT18, and KRT19) of >10 transcripts per million ( n = 30) were reclassified using the same KNN classifier as in A . Survival differences between the reclassified Low_CTC samples recapitulates the differences in survival outcome seen between the four CTC phenotypes in the high-purity CTC samples.
Year:
2025
Gene expression of epithelial and prostate adenocarcinoma–associated genes across CTC phenotypes. A, Schematic of the CTC transcriptional phenotypes. B and C, Epithelial keratin ( KRT8 and KRT18 ) gene expression across phenotypes; for patients with multiple CTC samples, the highest purity sample is included (Low_CTC, n = 30; Low_prolif, n = 12; LumA, n = 24; LumB, n = 31; and NE, n = 3). D, KLK3 (PSA), ( E ) FOLH1 (PSMA), and ( F ) MKI67 (Ki-67) gene expression across phenotypes; for patients with multiple CTC samples, the highest purity sample is included (Low_CTC, n = 30; Low_prolif, n = 12; LumA, n = 24; LumB, n = 31; and NE, n = 3).
Year:
2025
Luminal-B CTC phenotype is associated with poor prognosis and adverse clinical features. A, Serum PSA (ng/mL) at the time of CTC collection in the survival analysis subset (Low_CTC, n = 63; Low_prolif, n = 12; LumA, n = 21; LumB, n = 18; and NE, n = 3). B, Proportion of samples in each CTC transcriptional phenotype for each disease category in the survival analysis subset (mCSPC, n = 20; mCRPC, n = 93; and NEPC, n = 4) is shown. C, Kaplan–Meier plot of the OS from the time of the first CTC collection for each patient ( n = 117) by CTC transcriptional phenotype at the first CTC collection. Median survival, and HR and log-rank P value relative to low CTC burden (Low_CTC) phenotype are shown in the inset. Risk table is shown below. D, Multivariate analysis of the CTC phenotype clustersgroups demonstrates that LumB remains a poor prognostic factor after adjusting for adverse clinical features. E, Distribution of CTC transcriptional phenotypes by metastatic sites involved at the time of the first CTC collection including lymph node only (LN only, n = 7), bone ± lymph node (bone ± LN, n = 64), at least one non-liver soft-tissue site (non-liver visceral, n = 14), and at least one liver site (liver, n = 20).
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (44)
Meng Zhang
Assistant Professor of Urology
Emory University
Weibo Cai
University of Wisconsin-Madison
Andrew Armstrong
Professor
Duke Cancer Institute
Angelica Lin
University of Michigan
Blake Wilde
Assistant Professor
Roswell Park Comprehensive Cancer Center
Grace Blitzer
University of Wisconsin-Madison
David A. Quigley
Assistant Professor
University of California, San Francisco
Joshua Lang
Professor
University of Wisconsin-Madison
Yoshie Umemura
Barrow Neurological Institute
Scott Tagawa
Weill Cornell Medicine
Abigail Jackson
University of Utah
HAMID EMAMEKHOO
University of Wisconsin-Madison
Rendong Yang
Associate Professor
Northwestern University Feinberg School of Medicine
Yatrik Shah
Professor
University of Michigan
Liguo Wang
Professor of Biomedical Informatics
Mayo Clinic Minnesota
Reinier Hernandez
Assistant Professor
University of Wisconsin-Madison
Labros Meimetis
Stony Brook University
Marc Peters-Golden
Professor
University of Michigan
Michael Haffner
Fred Hutchinson Cancer Research Center
Elisabeth I. Heath
Wayne State University School of Medicine
Andrew S. Goldstein
Associate Professor
University of California
Weihua Zhou
Assistant Professor
University of Michigan
David Kosoff
University of Wisconsin-Madison
Jonathan W Engle
Associate Professor
University of Wisconsin-Madison
Menggang Yu
Professor
University of Michigan
Eric J. Small
University of California, San Francisco
Scott M Dehm
Faculty, Professor
University of Minnesota
Marina N Sharifi
Assistant Professor
University of Wisconsin-Madison
Manish Kohli
Professor
Huntsman Cancer Institute
Arian Lundberg
Assistant Professor at KTH Royal Institute of Technology
KTH Royal Institute of Technology
Felix Y. Feng
University of California
Atish Choudhury
Dana-Farber Cancer Institute
Sheena C Kerr
Research Assistant Professor
University of Wisconsin-Madison
Aaron M. LeBeau
Associate Professor
University of Wisconsin School of Medicine and Public Health
Erika Heninger
University of Wisconsin-Madison
David J. Beebe
University of Wisconsin-Madison
THEODORE S. LAWRENCE
Chair, Professor
University of Michigan
Peter S. Nelson
Fred Hutchinson Cancer Research Center
Heather Christofk
Professor
David Geffen School of Medicine at UCLA
Rahul Aggarwal
University of California
Rana R. McKay
University of California, San Diego
Daniel R. Wahl
University of Michigan
Costas A. Lyssiotis
University of Michigan
Paul C Boutros
University of California
Make your next move.
Prepare your application
Review drafts before you send them.